Life Sciences AI Implementation: How a Mid-Sized Biotech Validated an AI System for Clinical Trial Protocol Optimization
When a 1,200-person biopharmaceuticals company decided to address its protocol amendment crisis—averaging 4.7 amendments per Phase 2/3 trial and extending timelines by 8-12 months—the clinical operations team knew traditional document review processes had reached their limits. With twelve programs in active clinical development and mounting pressure to accelerate pivotal studies, leadership approved an initiative to implement artificial intelligence for protocol design optimization. The goal was ambitious: reduce protocol amendments by 40% within eighteen months by using machine learning to identify inclusion/exclusion criteria conflicts, endpoint feasibility issues, and procedural complexity that historically triggered mid-trial changes. What followed was a two-year journey that transformed initial enthusiasm into hard-won validation success, offering lessons for any organization attempting to bring AI tools into GCP-regulated environments. This case study examines the complete Life S...